This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2014.
For an indepth analysis of these deals, read ‘Pharma deals during January 2015’
|
Licensor acquired / licensee acquirer |
Product / technology |
Deal type |
Headline ($m) |
| NPS/Shire | NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome | Corporate acquisition | 5,200 |
| Foundation Medicine/Roche | Broad R&D collaboration to optimise oncology treatments via Foundations genomic analysis and molecular information | Majority interest acquisition | 1,180 |
| Kite Pharma/Amgen | Chimeric Antigen Receptor (CAR) T cell immunotherapy engineered autologous cell therapy (eACT) platform, Amgen contribute cancer targets | Licence collaboration agreement | 1,110 |
| Janssen/ Depomed | Nucynta [tapentadol] franchise including extended release tablets and oral solutions | Divestment of US rights | 1,050 |
| Esteve/ Mundipharma | Discovery and development of next generation pain products including E-52862 in P2 for neuropathic pain | Strategic collaboration | 1,000 |
| Isis/ Janssen | Antisense drugs to treat autoimmune disorders of the GI tract – local and oral therapies (3 programmes) | Collaboration to discover and develop candidates | 835 |
| Fedora and Meiji Seika/Roche | Roche secures rights to OP0595 a beta lactamase inhibitor in P1 clinical development against multi drug resistant bacteria | Licence agreement | 750 |
| Convergence/Biogen Idec | Includes a neuropathic pain portfolio with CNV 1014802 in P2 for trigeminal neuralgia | Corporate acquisition | 675 |
| Trophos/Roche | Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury | Corporate acquisition | 545 |
| Cytos Biotechnology/ OnCore | Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases | Exclusive licence | 522 |
| AC Immune/ Janssen | To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer’s disease | 3 year research collaboration and exclusive licence | 509 |
| Neuropore Therapies/UCB | To develop and commercialise NPT200-11 and other therapeutic products for Parkinson’s disease | Collaboration agreement | 480 |
| PneumRx/BTG | Includes RePneu a coil to open airways in emphysema patients | Corporate acquisition | 475 |
| Phenex/Gilead | Small molecules targeting FXR Farnesoid X receptor (FXR) programme Px102, Px104 in P2 development in Non-Alcoholic Steatohepatitis [NASH] | Asset acquisition | 470 |
| Auden Mckenzie/Actavis | Purchase includes generic portfolio of 175 products making Actavis no 1 generic supplier in the UK | Corporate acquisition | 458 |
| Agenus/Incyte | Using Agenus’ antibody discovery platform focusing on 4 checkpoint modulator programmes includes $35m equity | Licence to develop and commercialise | 410 |
| Aurigene /Curis | 2 programmes including IRAK4 Inhibitors and small molecule antagonist of programmed death [PD-L1] | Collaboration and option to a licence | 346 |
| Vedanta /J&J | Microbiome-based drug candidate VE202 for bowel diseases, Crohn’s disease and ulcerative colitis | Licence to develop anti-bacterial VE202 | 241 |
| OnCyte/Cardio3 | Acquisition of the oncology division of Celdara Medical including CM-CS1 an autologous CAR-T cell drug candidate which uses NKG2D to target tumour antigens | Asset acquisition | 180 |
| ZymeWorks/Celgene | Development of multiple bi-specific antibodies using the Azymetric platform | Licence, option and collaboration | 164 |
| Novartis/Aspen | Purchase of the heparin based anticoagulant Mono-Embolex, with sales of €68m in 2013 | Asset acquisition | 142 |
| Amunix/Naia | To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel syndrome | 2 exclusive licences | 140 |
